KFA-027

KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections[1].

Product Specifications

UNSPSC

12352005

Target

HIV

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

CC(C#CC1=NC([C@@H](NC(CN2N=C(C3=C2C(F)([C@H]4[C@@H]3C4)F)C(F)(F)F)=O)CC5=CC=CC=C5)=C(C=C1)C6=C7C(C(NS(C)(=O)=O)=NN7CC(F)(F)F)=C(C=C6)Cl)(S(C)(=O)=O)C

Molecular Formula

C39H34ClF8N7O5S2

Molecular Weight

932.30

References & Citations

[1]Adu-Ampratwum D, et al. Delineating Structural Functionalities of Lenacapavir Amenable to Modifications for Targeting Emerging Drug-Resistant HIV‑1 Capsid Variants. ACS Med Chem Lett. 2025 Sep 23;16 (10) :2007-2014.